We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)
References
REFERENCES
1
1.Greenberg, BD, George, MS, Benjamin, J, et al.Effect of prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: a preliminary study. Am J Psychiatry. 1997;154:867–869.Google ScholarPubMed
3.Corá-Locatelli, G, Greenberg, BD, Martin, JD, Murphy, DL. Rebound psychiatric and physical symptoms after gabapentin discontinuation. J Clin Psychiatry. In press.Google Scholar
4
4.Corá-Locatelli, G, Greenberg, BD, Martin, J, Leong, Y-M, Murphy, DL. Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder Submitted.Google Scholar
5
5.Broocks, A, Pigott, TA, Hill, JL, et al.Acute administration of ondansetron and m-cpp, alone and in combination, in patients with obsessive-compulsive disorder (OCD) and controls: behavioral and biological results. Psychiatry Research. In press.Google Scholar
6
6.Broocks, A, Briggs, NC, Pigott, TA, et al.Behavioral, physiological, and neuroendocrine responses in healthy volunteers to m-chlorophenylpiperazine (m-CPP) with and without ondansetron pretreatment. Psychopharmacology. 1997;130:91–103.CrossRefGoogle ScholarPubMed
7
7.Altemus, M, Glowa, JR, Galliven, E, Leong, YM, Murphy, DL. Effects of serotonergic agents on food-restriction-induced hyperactivity. Pharmacol Biochem Behav. 1996;53:123–131.CrossRefGoogle ScholarPubMed
8
8.Altemus, M, Murphy, DL. Animal models of obsessive-compulsive disorder. In: Westenberg, HGM, Murphy, DL, Den Boer, JA, eds. Advances in the Neurobiology of Anxiety Disorder. New York: Wiley, 1996:249–278.Google Scholar
9
9.Bengel, D, Murphy, DL, Andrews, AM, et al.Altered brain serotonin (5-HT) homeostasis and locomotor insensitivity to MDMA (“ecstasy”) in 5-HT transporter-deficient mice. Molecular Pharm. 1998;53:649–655.CrossRefGoogle ScholarPubMed
10
10.Murphy, DL, Greenberg, B, Altemus, M, Benjamin, J, Grady, T, Pigott, T. The neuropharmacology and neurobiology of obsessive-compulsive disorder: an update on the serotonin hypothesis. In: Westenberg, HGM, Murphy, DL, Den Boer, JA, eds. Advances in Neurobiology of Anxiety. 1996;2:279–298.Google Scholar
11
11.Murphy, DL, Andrews, AM, Wichems, CH, Li, Q, Greenberg, B. Brain serotonin neurotransmission: an overview and update with an emphasis on serotonin subsystem heterogeneity, multiple receptors interactions with other neurotransmitter systems, and consequent implications for understanding the actions of serotonergic drugs. J Clin Psychiatry. In press.Google Scholar
12
12.Weiger, WA. Serotonergic modulation of behaviour: a phylogenetic overview. Biol Rev. 1996;72:61–95.CrossRefGoogle Scholar
13
13.Karayiorgou, M, Altemus, M, Galke, BL, et al.Genotype determining low catechol-o-methyltransferase activity as a risk factor for obsessive-compulsive disorder. Proc Natl Acad Sci USA. 1997;94:4572–4575.Google Scholar